Cullinan Therapeutics - Funding, Financials, Valuation & Investors

Feb 5, 2019 · Cullinan Therapeutics is registered under the ticker NASDAQ:CGEM . Their stock opened with $21.00 in its Jan 7, 2021 IPO. Cullinan Therapeutics is funded by 25 investors. …

CouponFollow Extension

$21.00
OFF

Cullinan Therapeutics - Funding, Financials, Valuation & Investors

20 hours ago

Feb 5, 2019 · Cullinan Therapeutics is registered under the ticker NASDAQ:CGEM . Their stock opened with $21.00 in its Jan 7, 2021 IPO. Cullinan Therapeutics is funded by 25 investors. …

crunchbase.com

$280
OFF

Cullinan Therapeutics Announces Oversubscribed $280 Million …

20 hours ago

Apr 16, 2024 · Cullinan Therapeutics, Inc. Financing includes new and existing leading life sciences institutional investors. Proceeds, along with existing cash and cash equivalents, are …

yahoo.com

$280
OFF

Cullinan Therapeutics Announces Oversubscribed $280 Million

20 hours ago

Apr 16, 2024 · Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. We have strategically built a …

globenewswire.com

$280
OFF

Cullinan Therapeutics, Inc. Announces Oversubscribed $280

20 hours ago

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company …

massbio.org

$0.69
OFF

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired

20 hours ago

20 hours ago · Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th.The company reported ($0.69) earnings …

marketbeat.com

FAQs about Cullinan Therapeutics - Funding, Financials, Valuation & Investors Coupon?

Who is Cullinan Therapeutics?

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. ...

How many investors does Cullinan oncology have?

Cullinan Oncology has 17 investors including Foresite Capital and BVF Partners. How much funding has Cullinan Oncology raised to date? Cullinan Oncology has raised $389.7M. When was the last funding round for Cullinan Oncology? Cullinan Oncology closed its last funding round on Mar 31, 2022 from a Post-IPO Equity round. ...

What will Cullinan's funding do?

Proceeds from the financing are expected to be used to support Cullinan’s ongoing research and development activities, the expansion of its CD19xCD3 T cell engager clinical program for autoimmune diseases, as well as general corporate purposes and working capital. ...

Who is Cullinan oncology?

Cullinan Oncology is a developer of an externally sourced cancer therapeutics used to end a drug program quickly. View contacts for Cullinan Oncology to access new leads and connect with decision-makers. ...

Is Cullinan oncology a biopharmaceutical company?

CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that t... ...

How much money has Cullinan Oncology raised?

Cullinan Oncology has raised $389.7M. When was the last funding round for Cullinan Oncology? Cullinan Oncology closed its last funding round on Mar 31, 2022 from a Post-IPO Equity round. Who are Cullinan Oncology 's competitors? ...